Supplier News: Lonza, Adragos, Avantor & More
The latest from CDMOs, CMOs, and suppliers featuring Lonza, Avantor, Adragos Pharma, Gilero, Sekisui Cryoport and GenScript Biotech.
Chemicals/Chemical API Manufacturing
* Lonza To Expand Bioconjugation With Two New Mfg Suites
Biologics Manufacturing
* Sekisui Completes $21-M Drug Substance Mfg Facility Expansion
* Cryoport Opens New CoE for Cell Therapies
* Avantor Opens New Biomanufacturing Innovation Center
Formulation Development/Drug Product Manufacturing
* Adragos Pharma Adds New Ampoule Filling Line
* Genscript Sets Up New Operations & Logistics Site in Australia
Packaging
* Gilero Investing In New Injection Molding Mfg Facility
Chemicals/Chemical API Manufacturing
Lonza To Expand Bioconjugation With Two New Mfg Suites
Lonza has announced it will invest in additional bioconjugation capabilities in Visp, Switzerland. The expansion will add two multipurpose 1,200-L manufacturing suites and manufacturing-related infrastructure to the company’s existing bioconjugation facility in Visp for launch and commercial supply. The new capacity is expected to be operational from 2028. The new suites will occupy approximately 2,000 square meters and double Lonza’s capacity for the launch and commercial supply of bioconjugates. The suites are designed to run the processes needed to manufacture antibody-drug conjugates and other bioconjugates
Source: Lonza
Biologics Manufacturing
Sekisui Completes $21-M Biomanufacturing Mfg Facility Expansion
Sekisui Diagnostics’ microbial CDMO business, has completed construction of a £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade biologics drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types, including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for gene-therapy manufacture. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000 L.
Source: Sekisui
Cryoport Opens New CoE for Cell Therapies
Cryoport, a Nashville, Tennessee-based provider of supply-chain services, has opened a new Center of Excellence in Villers-le-Bouillet, Liege, Belgium.
The Center of Excellence is now fully operational and prepared to support the development and commercialization of cell-based therapies with advanced cryopreservation for leukapheresis, a common starting material. The 1,300-square-meter, custom-built, GMP-compliant cryopreservation facility expands Cryoport’s capabilities by developing, optimizing and validating cryogenic preservation methods for leukapheresis materials to meet the standards for cell-based therapies. The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually.
Source: Cryoport
Avantor Opens New Biomanufacturing Innovation Center
Avantor, a provider of products and services to the life sciences and advanced technologies industries, has opened a new Innovation Center in Bridgewater, New Jersey. The new center spans 60,000 square feet, doubling its previous laboratory and pilot-plant capacity. The center houses spaces for upstream and downstream process development, dedicated analytical testing labs, and a viral vector laboratory. An expanded pilot plant supports scale-up simulations across th bioprocessing workflow.
Source: Avantor
Formulation Development/Drug Product Manufacturing
Adragos Pharma Adds New Ampoule Filling Line
Adragos Pharma, a Munich, Germany-based CDMO of drug products, has announced the launch of a new ampoule filling line at its facility in Livron, France. The new line increases the company’s production capacity to over 160 million ampoules per year, with flexible fill volumes ranging from 1 mL to 20 mL. The new line marks the fourth line by the company and increases its capacity by 30%.
Source: Adragos Pharma
Genscript Sets Up New Operations & Logistics Site in Australia
GenScript Biotech, a Piscataway, New Jersey-based technology and service company, has announced the establishment of new operations site and logistics center in Sydney, Australia, for the delivery of research reagents and products. A highlight of the Sydney site is the introduction of next-day shipping for high-demand products such as off-the-shelf mRNA, growth factors, Cas proteins, and other products.
Source: GenScript Biotech
Packaging
Gilero Investing In New Injection Molding Mfg Facility
Gilero, a Durham, North Carolina-based medical device and drug-delivery company, is expanding its manufacturing capabilities with a new 60,500-square-foot facility in Greensboro, North Carolina, for producing components for medical devices and pharmaceutical packaging, as well as desiccant for moisture-sensitive drugs and devices.
The new Greensboro facility with Cleanroom Class 7 and 8 will house injection molding and desiccant filling machines, quality control laboratories, and will have humidity-controlled production areas. Production will begin in the second quarter of 2025.
Source: Gilero
